BRCTF.US BioArctic AB (publ)

Healthcare Biotechnology USA Stocks
36.20 USD
Close of Nov 2, 2026
29.28 38.75
Market cap
USD 2.69B
P/E
233.3x
P/B
13.18x
ROE
20.1%
Dividend yield
0.70%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BRCTF.US undervalued?

Graham number

The Graham number of BioArctic AB (publ) cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioArctic AB (publ) fundamental analysis

No fundamental analysis for BioArctic AB (publ) yet.

BioArctic AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatm…

Full company profile